TY - JOUR
T1 - Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor
AU - Frullanti, Elisa
AU - Berking, Carola
AU - Harbeck, Nadia
AU - Jézéquel, Pascal
AU - Haugen, Aage
AU - Mawrin, Christian
AU - Parise, Orlando
AU - Sasaki, Hidefumi
AU - Tsuchiya, Norihiko
AU - Dragani, Tommaso A.
PY - 2011/7
Y1 - 2011/7
N2 - Fibroblast growth factor receptor 4 (FGFR4) contains a Gly388Arg functional polymorphism (rs351855) that has shown contrasting results in association studies. In this study, we assessed the association between the FGFR4 Gly388Arg polymorphism and cancer prognosis. Meta-analysis and pooled analysis of 6817 and 2537 cancer cases, respectively, were carried out by nodal status and overall survival. The study included the following types of cancer: brain, breast, colorectal, head and neck, larynx, lung, melanoma, prostate, sarcomas. A statistically significant association between the Arg388Arg genotype and nodal involvement was found in the meta-analysis (odds ratio=1.33, 95% confidence interval 1.01-1.74). In the pooled analysis, the Arg388 allele carriers showed an increased hazard of poor overall survival compared with homozygous carriers of the common Gly388 allele, even after adjusting for nodal status (hazard ratio=1.21, 95% confidence interval 1.05-1.40). These results provide evidence of a role for the FGFR4 Gly388Arg polymorphism in modulating patients' outcome in different types of cancer, thus offering to clinicians a new marker to predict predisposition to poor survival in cancer patients.
AB - Fibroblast growth factor receptor 4 (FGFR4) contains a Gly388Arg functional polymorphism (rs351855) that has shown contrasting results in association studies. In this study, we assessed the association between the FGFR4 Gly388Arg polymorphism and cancer prognosis. Meta-analysis and pooled analysis of 6817 and 2537 cancer cases, respectively, were carried out by nodal status and overall survival. The study included the following types of cancer: brain, breast, colorectal, head and neck, larynx, lung, melanoma, prostate, sarcomas. A statistically significant association between the Arg388Arg genotype and nodal involvement was found in the meta-analysis (odds ratio=1.33, 95% confidence interval 1.01-1.74). In the pooled analysis, the Arg388 allele carriers showed an increased hazard of poor overall survival compared with homozygous carriers of the common Gly388 allele, even after adjusting for nodal status (hazard ratio=1.21, 95% confidence interval 1.05-1.40). These results provide evidence of a role for the FGFR4 Gly388Arg polymorphism in modulating patients' outcome in different types of cancer, thus offering to clinicians a new marker to predict predisposition to poor survival in cancer patients.
KW - cancer risk
KW - clinical stage
KW - genetic susceptibility
KW - overall survival
KW - single nucleotide polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=79958829857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958829857&partnerID=8YFLogxK
U2 - 10.1097/CEJ.0b013e3283457274
DO - 10.1097/CEJ.0b013e3283457274
M3 - Article
C2 - 21412156
AN - SCOPUS:79958829857
VL - 20
SP - 340
EP - 347
JO - European Journal of Cancer Prevention
JF - European Journal of Cancer Prevention
SN - 0959-8278
IS - 4
ER -